ScaleReady

ScaleReady provides an integrated manufacturing platform for the cell and gene therapy industry. It combines advanced tools for cell culture, activation, gene editing, and processing. Employing a G-Rex centric approach, the platform ensures linear scalability from R&D to commercial production, reducing complexity, cost, and upholding cell quality.

Formed in 2020, ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. This partnership arose from the insight that the nascent cell and gene therapy sector needed practical, scalable, and versatile manufacturing infrastructure. Leaders in their fields, these companies pooled expertise to address this critical industry bottleneck.

ScaleReady assists therapeutic developers in cell and gene therapy, facilitating efficient treatment progression. Its vision aims to accelerate groundbreaking therapies by building a robust, cost-effective, simplified manufacturing ecosystem. The company strives to make advanced cell and gene therapies accessible and viable.